Co not affected by geopolitical tensions in China - CEOLifts full-year EPS forecast
The Anglo-Swedish company said it managed to grow its business in China despite protracted COVID lockdowns and was no longer pursuingAstraZeneca is seen as a bellwether for the pharmaceutical sector in China, which accounted for about 16% of the company's total revenue last year. Despite the headwinds, the company generated 8% sales growth in the region on a constant currency basis in the quarter, whereas it had expected a decline, chief executive Pascal Soriot said on a media call.
Scumbags
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: